@article{e60a82556339497aafdb720fb06187f2,
title = "A path to translation: How 3D patient tumor avatars enable next generation precision oncology",
abstract = "3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.",
author = "{Shree Bose} and Margarida Barroso and Chheda, {Milan G.} and Hans Clevers and Elena Elez and Salma Kaochar and Kopetz, {Scott E.} and Li, {Xiao Nan} and Funda Meric-Bernstam and Meyer, {Clifford A.} and Haiwei Mou and Naegle, {Kristen M.} and Pera, {Martin F.} and Zinaida Perova and Politi, {Katerina A.} and Raphael, {Benjamin J.} and Paul Robson and Sears, {Rosalie C.} and Josep Tabernero and Tuveson, {David A.} and Welm, {Alana L.} and Welm, {Bryan E.} and Willey, {Christopher D.} and Konstantin Salnikow and Chuang, {Jeffrey H.} and Xiling Shen",
note = "Funding Information: We thank the NCI 3D Workshop, Patient-Derived Model of Cancer (PDMC) Program, and PDXNet for constructive discussions, recommendations, and purposeful efforts to advance the practice of precision oncology. This work was supported by National Cancer Institute grants NIH-U01CA217514 and U01CA214300 as well as National Institutes of Health F30 fellowship 1F30CA257365-01 . Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = dec,
day = "12",
doi = "10.1016/j.ccell.2022.09.017",
language = "English",
volume = "40",
pages = "1448--1453",
journal = "Cancer Cell",
issn = "1535-6108",
number = "12",
}